Latest news with #SartoriusStedimBiotech
Yahoo
13 hours ago
- Business
- Yahoo
3 European Stocks Estimated At Up To 41.3% Discount To Intrinsic Value
As European markets navigate the complexities of potential EU-U.S. trade deals and a slightly hawkish stance from the European Central Bank, investors are keenly observing opportunities that may arise from these developments. In this context, identifying stocks that are undervalued can be particularly appealing, as they offer potential value against a backdrop of cautious optimism in the market. Top 10 Undervalued Stocks Based On Cash Flows In Europe Name Current Price Fair Value (Est) Discount (Est) Talenom Oyj (HLSE:TNOM) €3.52 €6.95 49.3% Selvita (WSE:SLV) PLN35.50 PLN69.87 49.2% Logic Instrument (ENXTPA:ALLOG) €2.18 €4.32 49.5% Laboratorios Farmaceuticos Rovi (BME:ROVI) €55.75 €109.12 48.9% JOST Werke (XTRA:JST) €52.10 €102.82 49.3% Echo Investment (WSE:ECH) PLN5.36 PLN10.70 49.9% doValue (BIT:DOV) €2.548 €5.00 49% cyan (XTRA:CYR) €2.20 €4.36 49.5% BHG Group (OM:BHG) SEK24.50 SEK48.78 49.8% Atea (OB:ATEA) NOK143.60 NOK282.50 49.2% Click here to see the full list of 194 stocks from our Undervalued European Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Sartorius Stedim Biotech Overview: Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry globally, with a market cap of €17.47 billion. Operations: The company's revenue is primarily derived from its Biopharm segment, which generated €2.90 billion. Estimated Discount To Fair Value: 12.6% Sartorius Stedim Biotech's recent earnings report shows strong cash flow with a net income increase to €68.5 million for Q2 2025, up from €47.6 million the previous year. The stock trades at approximately 12.6% below its estimated fair value of €205.46 and is expected to see significant earnings growth of 27.49% per year, outpacing the French market average. Despite high debt levels, strategic expansions and partnerships bolster its long-term prospects in biopharmaceutical manufacturing. Upon reviewing our latest growth report, Sartorius Stedim Biotech's projected financial performance appears quite optimistic. Get an in-depth perspective on Sartorius Stedim Biotech's balance sheet by reading our health report here. Landis+Gyr Group Overview: Landis+Gyr Group AG, along with its subsidiaries, offers integrated energy management solutions to the utility sector across the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions and has a market cap of CHF1.99 billion. Operations: The company's revenue is primarily derived from its operations in the Americas ($967.49 million), Europe, the Middle East, and Africa (EMEA) ($639.04 million), and the Asia Pacific region ($158.68 million). Estimated Discount To Fair Value: 18.3% Landis+Gyr Group's stock is trading at CHF69.2, approximately 18.3% below its estimated fair value of CHF84.73, suggesting potential undervaluation based on cash flows. The company's revenue is forecast to grow by 6.7% annually, surpassing the Swiss market average of 4%. Recent agreements with Withlacoochee River Electric Cooperative and advancements in smart grid technology may enhance future cash flows despite current profitability challenges and a recent net loss of US$150.46 million for fiscal year 2025. Our comprehensive growth report raises the possibility that Landis+Gyr Group is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Landis+Gyr Group. Overview: S.A. operates a leading commerce platform for consumers in Poland and internationally, with a market cap of PLN38.86 billion. Operations: generates revenue from its core commerce platform, serving consumers both in Poland and internationally. Estimated Discount To Fair Value: 41.3% is trading at PLN36.89, significantly below its estimated fair value of PLN62.85, indicating it may be undervalued based on cash flows. The company reported Q1 2025 sales of PLN2.62 billion and net income of PLN296.5 million, showing growth from the previous year. Earnings are projected to grow at 20.65% annually, outpacing the Polish market's average growth rate while revenue is expected to increase by 10.2% per year. The growth report we've compiled suggests that future prospects could be on the up. Click to explore a detailed breakdown of our findings in balance sheet health report. Summing It All Up Reveal the 194 hidden gems among our Undervalued European Stocks Based On Cash Flows screener with a single click here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:DIM SWX:LAND and WSE:ALE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa's biopharmaceutical industry and address the continent's urgent, dual health burdens in infectious and non-communicable diseases. This collaboration will focus on developing and manufacturing affordable, high-quality monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. The agreement will also cover joint initiatives in workforce development, process innovation, and technology transfer. "Africa is at a critical juncture in its health trajectory. We are battling a twin epidemic of infectious diseases and a rapidly rising burden of non-communicable diseases such as cancer and diabetes. Yet, lifesaving innovations often do not reach the continent due to high costs and late availability," said Dr. Menghis Bairu, CEO of Bio Usawa. "Our partnership with Sartorius Stedim Biotech is transformational—it allows us to bring advanced biomanufacturing technology to Africa, train a new generation of African scientists, and produce innovative biopharmaceuticals that are accessible and affordable for our people." The partnership includes the following core pillars: Research & Development: Sartorius Stedim Biotech will collaborate with Bio Usawa to develop state-of-the-art biosimilar cell lines tailored to therapeutic needs in Africa. Workforce Capacity Building: The companies will jointly design and deliver training programs for the African biopharma workforce, nurturing local talent for long-term sustainability. Technology Enablement: Sartorius Stedim Biotech will supply state-of-the-art bioprocessing equipment, media, buffers, and consumables for both upstream and downstream (drug substance and fill-finish) manufacturing. Optimization: Sartorius Stedim Biotech will provide its deep expertise in process optimization, ensuring robust, scalable, cost-effective and compliant manufacturing processes. Analytical and QC Support: Sartorius Stedim Biotech's capabilities in analytical characterization and quality control testing will strengthen Bio Usawa's product quality assurance framework. 'At Sartorius Stedim Biotech, we believe in enabling breakthroughs that improve human health, no matter where patients live,' said Michaela Pischke, Head of Business Area Separation Technologies at Sartorius Stedim Biotech. 'Our partnership with Bio Usawa reflects a shared ambition: supporting biopharmaceutical supply in Africa from the ground up. Through this collaboration, we aim not only to support technical innovation but also to empower local talent and infrastructure development to ensure long-term, self-sustaining impact.' With this partnership, Bio Usawa will leverage the extensive biotech product development, clinical trial, and regulatory expertise of its leadership team — across both developed and developing markets — to drive innovation tailored for Africa. This initiative represents a bold step forward in building Africa's health sovereignty, delivering on the promise of equitable access to life-saving innovations and shaping the future of healthcare on the continent. About Bio Usawa Inc. Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies. For more information, visit: About Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Media Contacts: Contact Bio UsawaDaniel LevineLevine Media Group+1 510-280-5405danny@ Contact Sartorius Stedim Biotech GmbHLars HanfHead of BPS Marketing Communications+ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
6 days ago
- Business
- Reuters
European shares end lower as corporate results, trade anxiety weigh
July 22 (Reuters) - European shares settled lower on Tuesday, with German equities logging their biggest one-day drop in two months as a batch of disappointing corporate reports and dimming prospects of a U.S.-European Union trade deal weighed on sentiment. The pan-European STOXX 600 index (.STOXX), opens new tab closed 0.46% lower, with Germany's DAX (.GDAXI), opens new tab logging a 1.1% drop, easing further from a recent record high. This earnings season is especially of interest for investors as they look for clues on how trade uncertainty and the euro's recent surge are impacting European export-heavy corporates. Latest earnings forecasts showed the outlook for European corporate health has slightly improved, although they are still expected to drop 0.3% on average, according to data compiled by LSEG. A year ago, STOXX 600 companies on average delivered a 3.0% increase in second-quarter earnings. On Monday, Sartorius Stedim Biotech ( opens new tab was among top losers on the STOXX 600, down 8.1% after the French lab supplies manufacturer reported its half-year results. Switzerland's Givaudan (GIVN.S), opens new tab lost 5.4% after missing half-year sales forecast due to the Swiss franc's 14% surge this year. Among major lenders, Julius Baer's (BAER.S), opens new tab first half profit took a hit, pressured by loan loss provisions and a charge from the sale of its Brazilian wealth management arm, sending shares of the Swiss bank down 2.1%. Keeping investors wary was also the lack of progress on prolonged negotiations between the U.S. and Europe as they brace for the EU potentially announcing a broader range of counter-measures against Washington and could escalate trade tensions. "If we see that 30% (U.S.) tariff implemented, followed by potential countermeasures from the European Union, it would significantly hurt the growth outlook for the eurozone—a region where growth is already in a very fragile position," Fiona Cincotta, senior market analyst at City Index said. Top on the radar for investors is a business activity survey and the European Central Bank's monetary policy verdict later in the week. Markets broadly anticipate that the central bank would leave interest rates unchanged. "The ECB essentially has their hands tied at the moment until they gain more clarity on what the trade relationship with the U.S. will look like," Cincotta said. Among others, Dulux paint maker Akzo Nobel ( opens new tab declined 3.4% after lowering its core profit outlook for 2025, while Swiss chocolate maker Lindt & Spruengli (LISN.S), opens new tab fell 6.4% as steep hikes in chocolate prices struck half-year volumes. In bright spots, Britain's Compass Group (CPG.L), opens new tab surged 5.4% after the food catering firm agreed to buy European premium food services business Vermaat Groep in a 1.5-billion-euro ($1.75 billion) deal including debt. Banco BPM ( opens new tab closed up 1.2% after Italy's market watchdog has suspended UniCredit's ( opens new tab bid for the lender for another 30 days. Attention will be on SAP ( opens new tab, the region's largest company by market cap, with its results due later in the day.
Business Recorder
23-07-2025
- Business
- Business Recorder
European shares end lower as trade anxiety weigh
FRANKFURT: European shares settled lower on Tuesday, with German equities logging their biggest one-day drop in two months as a batch of disappointing corporate reports and dimming prospects of a US-European Union trade deal weighed on sentiment. The pan-European STOXX 600 index closed 0.46% lower, with Germany's DAX logging a 1.1% drop, easing further from a recent record high. This earnings season is especially of interest for investors as they look for clues on how trade uncertainty and the euro's recent surge are impacting European export-heavy corporates. Latest earnings forecasts showed the outlook for European corporate health has slightly improved, although they are still expected to drop 0.3% on average, according to data compiled by LSEG. A year ago, STOXX 600 companies on average delivered a 3.0% increase in second-quarter earnings. On Monday, Sartorius Stedim Biotech was among top losers on the STOXX 600, down 8.1% after the French lab supplies manufacturer reported its half-year results. Switzerland's Givaudan lost 5.4% after missing half-year sales forecast due to the Swiss franc's 14% surge this major lenders, Julius Baer's first half profit took a hit, pressured by loan loss provisions and a charge from the sale of its Brazilian wealth management arm, sending shares of the Swiss bank down 2.1%. Keeping investors wary was also the lack of progress on prolonged negotiations between the US and Europe as they brace for the EU potentially announcing a broader range of counter-measures against Washington and could escalate trade tensions. 'If we see that 30% (US) tariff implemented, followed by potential countermeasures from the European Union, it would significantly hurt the growth outlook for the eurozone—a region where growth is already in a very fragile position,' Fiona Cincotta, senior market analyst at City Index said. Top on the radar for investors is a business activity survey and the European Central Bank's monetary policy verdict later in the week. Markets broadly anticipate that the central bank would leave interest rates unchanged.
Business Times
22-07-2025
- Business
- Business Times
Europe: Shares end lower as corporate results, trade anxiety weigh
EUROPEAN shares settled lower on Tuesday, with German equities logging their biggest one-day drop in two months as a batch of disappointing corporate reports and dimming prospects of a US-European Union trade deal weighed on sentiment. The pan-European Stoxx 600 index closed 0.41 per cent lower at 544.34, with Germany's DAX logging a 1.1 per cent drop, easing further from a recent record high. This earnings season is especially of interest for investors as they look for clues on how trade uncertainty and the euro's recent surge are impacting European export-heavy corporates. Latest earnings forecasts showed the outlook for European corporate health has slightly improved, although they are still expected to drop 0.3 per cent on average, according to data compiled by LSEG. A year ago, Stoxx 600 companies on average delivered a 3.0 per cent increase in second-quarter earnings. On Monday, Sartorius Stedim Biotech was among top losers on the Stoxx 600, down 8.1 per cent after the French lab supplies manufacturer reported its half-year results. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Switzerland's Givaudan lost 5.4 per cent after missing half-year sales forecast due to the Swiss franc's 14 per cent surge this year. Among major lenders, Julius Baer's first half profit took a hit, pressured by loan loss provisions and a charge from the sale of its Brazilian wealth management arm, sending shares of the Swiss bank down 2.1 per cent. Keeping investors wary was also the lack of progress on prolonged negotiations between the US and Europe as they brace for the EU potentially announcing a broader range of counter-measures against Washington and could escalate trade tensions. 'If we see that 30 per cent (US) tariff implemented, followed by potential countermeasures from the European Union, it would significantly hurt the growth outlook for the eurozone - a region where growth is already in a very fragile position,' Fiona Cincotta, senior market analyst at City Index said. Top on the radar for investors is a business activity survey and the European Central Bank's monetary policy verdict later in the week. Markets broadly anticipate that the central bank would leave interest rates unchanged. 'The ECB essentially has their hands tied at the moment until they gain more clarity on what the trade relationship with the US will look like,' Cincotta said. Among others, Dulux paint maker Akzo Nobel declined 3.4 per cent after lowering its core profit outlook for 2025, while Swiss chocolate maker Lindt & Spruengli fell 6.4 per cent as steep hikes in chocolate prices struck half-year volumes. In bright spots, Britain's Compass Group surged 5.4 per cent after the food catering firm agreed to buy European premium food services business Vermaat Groep in a 1.5-billion-euro (S$2.2 billion) deal including debt. Banco BPM closed up 1.2 per cent after Italy's market watchdog has suspended UniCredit's bid for the lender for another 30 days. Attention will be on SAP, the region's largest company by market cap, with its results due later in the day. REUTERS
